Literature DB >> 109598

Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children.

.   

Abstract

Fifty-four children with steroid-responsive nephrotic syndrome relapsing within 6 months of their initial response were randomly allocated to receive two different regimens of prednisone therapy. The test regimen differed from the standard prednisone relapse regimen used by the International Study of Kidney Disease in Children in that the total dosage was about double, and the duration of daily therapy (8 weeks vs. a mean of 12 days) as well as the total duration of treatment (8 weeks vs. a mean of approximately 6 weeks) was longer. The proportion of patients relapsing during treatment was significantly smaller (8% vs. 40%) and the length of remission following treatment was significantly longer (3.27 vs. 1.48 months) in the test group. All patients in both groups relapsed by 8 months. During a period of approximately 6 months after this relapse, neither the frequency of relapses nor the mean number of days of proteinuria differed significantly. Opinions of participants in this multicenter trial varied concerning whether these statistically significant differences clinically justified exposing patients to the more intensive treatment regimen. However, all agreed that neither form of treatment was satisfactory in terms of preventing subsequent relapses.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 109598

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  34 in total

1.  Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.

Authors:  Akio Nakamura; Ryo Niimi; Kumiko Kurosaki; Yukishige Yanagawa
Journal:  Clin Exp Nephrol       Date:  2010-07-17       Impact factor: 2.801

2.  Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.

Authors:  Vaishnavi Raman; Sriram Krishnamurthy; K T Harichandrakumar
Journal:  Pediatr Nephrol       Date:  2016-01-12       Impact factor: 3.714

3.  Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.

Authors:  Bethany J Foster; Justine Shults; Babette S Zemel; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

4.  Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.

Authors:  Menka Yadav; Aditi Sinha; Priyanka Khandelwal; Pankaj Hari; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2018-09-07       Impact factor: 3.714

Review 5.  Treatment of steroid sensitive nephrotic syndrome.

Authors:  A S Abeyagunawardena
Journal:  Indian J Pediatr       Date:  2005-09       Impact factor: 1.967

Review 6.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

7.  Peritoneal protein losses in children with steroid-resistant nephrotic syndrome on continuous-cycler peritoneal dialysis.

Authors:  Sashikala Kopanati; Michel Baum; Albert Quan
Journal:  Pediatr Nephrol       Date:  2006-05-20       Impact factor: 3.714

Review 8.  Immunosuppressive therapy in the nephrotic syndrome in children.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

Review 9.  Minimal Change Disease.

Authors:  Marina Vivarelli; Laura Massella; Barbara Ruggiero; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-09       Impact factor: 8.237

10.  Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome.

Authors:  Koichi Nakanishi; Kazumoto Iijima; Kenji Ishikura; Hiroshi Hataya; Hitoshi Nakazato; Satoshi Sasaki; Masataka Honda; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.